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Abstract 
An increasing number of patients receive anticoagulant therapy to prevent and treat 
arterial or venous thromboembolism. The major complication of anticoagulant therapy is 
the increase of the individual bleeding risk. All anticoagulant drugs can cause 
haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin 
K antagonists have been the most widely used anticoagulants for decades, the correct 
management of bleeding complications associated with these agents has been poorly 
studied. More recently, new anticoagulant drugs, both parenteral and oral, have been 
approved for clinical use. Currently, none of these new agents has a specific antidote, and 
little advise can be given on how to manage a major bleeding event. The aim of this article 
is to describe the haemorrhagic risk and the management of bleeding complications 
associated with the principal anticoagulant drugs	  
